Protagonist Ther SEC Filings

Protagonist Therapeutics (PTGX) stockholder Arturo Molina MD has filed a Rule 144 notice to sell 9,514 common shares through Morgan Stanley Smith Barney on NASDAQ. The planned sale has an aggregate market value of $784,714.72, compared with a total of 62,515,666 common shares outstanding. The shares relate to restricted stock that vested under a registered plan on 01/20/2026, with services rendered as the form of payment.

The form also discloses that the same seller previously sold 2,712 common shares on 11/17/2025 for gross proceeds of $229,896.24. By signing, the seller represents they are not aware of any undisclosed material adverse information about Protagonist Therapeutics’ operations.

A holder of PTGX common stock has filed a notice of proposed sale under Rule 144. The filing covers 34,438 shares of common stock, to be sold through Morgan Stanley Smith Barney on the Nasdaq, with an indicated aggregate market value of $2,840,446.24. The filing notes that there were 62,515,666 shares of this class outstanding at the time of the notice.

The shares to be sold were acquired on 01/20/2026 through the vesting of restricted stock under a registered plan, with “services rendered” listed as the form of payment. The person for whose account the securities are to be sold represents that they do not know of any material adverse, non‑public information about the issuer’s current or prospective operations.

A holder of the issuer’s common stock has filed a notice of proposed sale under Rule 144 for 8,588 shares. The planned sale is to be executed through Morgan Stanley Smith Barney on or about 01/20/2026, with an indicated aggregate market value of 708,338.24. The issuer reports 62,515,666 shares outstanding, which is a baseline figure for the company’s equity.

The shares to be sold were acquired as restricted stock vesting under a registered plan from the issuer on 01/20/2026, as compensation for services rendered. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

Protagonist Therapeutics director Harold E. Selick reported exercising a stock option on 01/09/2026, converting 14,299 stock options with an exercise price of $4.21 into 14,299 shares of common stock. The transaction is coded “M,” indicating an option exercise.

Following this transaction, Selick directly beneficially owns 60,845 shares of Protagonist Therapeutics common stock. The filing notes that the stock options exercised were fully vested and that no derivative securities of this option grant remain outstanding.

Protagonist Therapeutics, Inc. reported that it has made an updated corporate presentation available as of January 12, 2026. The presentation is provided as Exhibit 99.1 to a current report on Form 8-K under Regulation FD, which is intended to share information broadly with the market. The company notes that this information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.

Protagonist Therapeutics director William D. Waddill reported new equity awards from the company. On January 2, 2026, he received 2,695 restricted stock units of common stock at a price of $0, bringing his directly held common stock to 7,825 shares after the grant. These restricted stock units vest in full on January 15, 2027, as long as he continues serving the company.

He also received a stock option for 3,762 shares of common stock with an exercise price of $87.18 per share. The option vests in 12 equal monthly installments following January 2, 2026, subject to his continued service, and expires on January 2, 2036. Both awards are reported as directly owned.

Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported equity awards on Form 4. On January 2, 2026, he received 95,400 shares of common stock as a grant of restricted stock units at a stated price of $0. These units are payable solely in common stock and will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, contingent on his continued service.

On the same date he was also granted a stock option for 120,200 shares of common stock with an exercise price of $87.18. This option vests in 48 equal monthly installments following January 2, 2026, also subject to continued service, and had 120,200 derivative securities beneficially owned after the transaction. Following the restricted stock grant, he beneficially owned 614,943 shares of common stock directly.

Protagonist Therapeutics, Inc. (PTGX) reported an insider equity change involving its President and CEO, who is also a director. On 11/21/2025, the reporting person made a bona fide gift of 440 shares of common stock, identified with transaction code "G" for a gift. The filing notes that the gift was made to the reporting person’s grandchild.

Following this gift transaction, the reporting person beneficially owns 519,543 shares of PTGX common stock, held directly. This Form 4 reflects a personal, non-sale transfer and does not describe any purchase or sale of shares on the market.

Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer. On 11/17/2025, Chief Medical Officer Arturo Molina reported selling 2,712 shares of common stock at a price of $84.77 per share. The sale was made to cover tax withholding obligations incurred when restricted stock units settled, rather than as an open-market discretionary sale.

Following this transaction, Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock in direct form. The filing was made by a single reporting person and does not list any derivative securities transactions.